In short
Clinical trials are investigating Triptorelin Pamoate as part of treatment studies for hormone naive prostate cancer. These trials look at how well it works in comparison with other androgen deprivation therapy (ADT) options and measure outcomes such as PSA response. The main focus is on adult patients with prostate cancer who have not yet received hormone treatment.
Key points
- Clinical trials of Triptorelin Pamoate are being done in hormone naive prostate cancer. The listed study is a Phase 2 interventional trial with 169 participants. It looks at PSA response at 24 weeks, defined as an 80% or greater drop from baseline. The study compares Triptorelin Pamoate and other ADT options with an internal control group. The main goal is to understand how treatment responses compare in patients who have not yet had hormone therapy.
Trial overview
The listed study is an interventional study, which means researchers assign treatments and then measure the results. It is a Phase 2 trial, so it is focused on learning more about how well the treatment works while also collecting more information about safety and response.
This trial is authorised and includes 169 participants. The condition being studied is hormone naive prostate cancer, which means prostate cancer in people who have not yet had hormone treatment.
Study design and treatment groups
The trial compares darolutamide with several androgen deprivation therapy (ADT) options, and Triptorelin Pamoate is one of the ADT treatments listed in the study. Other study drugs include degarelix, leuprorelin, triptorelin, and goserelin.
The trial summary says the ADT arm is used as an internal control, meaning it serves as a comparison group inside the same study. This helps researchers judge whether the main study arm reaches similar PSA response rates after 24 weeks.
Who can participate
The target population is people with hormone naive prostate cancer. In simple terms, these are patients who have prostate cancer but have not yet received hormone treatment.
The trial data do not list more detailed entry rules in the source provided, so the clearest eligibility information is the disease group itself.
Main outcomes measured
The primary endpoint is PSA response at 24 weeks. PSA stands for prostate-specific antigen, a blood marker used in prostate cancer follow-up.
In this trial, PSA response means a decline of at least 80% from the baseline value, which is the starting measurement before treatment begins. The brief summary says the main objective is to show that darolutamide produces PSA response rates in the range seen with 24 weeks of ADT.
What the results mean for patients
For patients, this trial is mainly about comparing treatment responses in early prostate cancer before hormone therapy has been used. The study does not report final results in the source provided, so it is best viewed as a research effort to measure how well the treatment approach performs over 24 weeks.
Because Triptorelin Pamoate is listed among the ADT options, it is part of the treatment comparison rather than the only focus of the study. The main patient-centered question is whether the treatment strategy can achieve a strong PSA drop in this group of men with hormone naive prostate cancer.